GLP-1 and SGLT-2 diabetes drugs may slow kidney damage, BMJ reports
Research summarized by BMJ Group suggests both drug classes could reduce progression of kidney injury in diabetes.
PR
By Priya Raman · Science Reporter
Sep 17 06:00 ETSource: BMJ Group
The wire
- 01BMJ Group reported that GLP-1 and SGLT-2 inhibitors may help slow kidney damage.
- 02Kidney protection would broaden the value of both classes beyond glucose and weight control.
- 03Effect sizes, study design and patient populations not detailed in the excerpt.
From the source
Read at news.google.comGLP-1 and SGLT-2 diabetes drugs may help slow kidney damage